Compass Therapeutics (CMPX) EBIAT (2023 - 2025)
Compass Therapeutics' EBIAT history spans 3 years, with the latest figure at -$15.7 million for Q4 2025.
- For Q4 2025, EBIAT fell 4.54% year-over-year to -$15.7 million; the TTM value through Dec 2025 reached -$66.5 million, down 34.66%, while the annual FY2025 figure was -$66.5 million, 34.66% down from the prior year.
- EBIAT for Q4 2025 was -$15.7 million at Compass Therapeutics, down from -$14.3 million in the prior quarter.
- Across five years, EBIAT topped out at -$7.8 million in Q1 2023 and bottomed at -$19.9 million in Q2 2025.
- The 3-year median for EBIAT is -$13.2 million (2023), against an average of -$13.2 million.
- The largest YoY upside for EBIAT was 4.54% in 2025 against a maximum downside of 54.19% in 2025.
- A 3-year view of EBIAT shows it stood at -$13.4 million in 2023, then decreased by 12.06% to -$15.0 million in 2024, then decreased by 4.54% to -$15.7 million in 2025.
- Per Business Quant, the three most recent readings for CMPX's EBIAT are -$15.7 million (Q4 2025), -$14.3 million (Q3 2025), and -$19.9 million (Q2 2025).